<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317028</url>
  </required_header>
  <id_info>
    <org_study_id>CS02-001</org_study_id>
    <nct_id>NCT03317028</nct_id>
    <nct_alias>NCT03308695</nct_alias>
  </id_info>
  <brief_title>CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Laboratories, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in&#xD;
      combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in&#xD;
      combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in&#xD;
      subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">April 21, 2020</completion_date>
  <primary_completion_date type="Actual">April 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The HbA1c treatment effect among CS02 groups and the Placebo group</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess 208 evaluable subject of the change in HbA1c from baseline to end of treatment among CS02 groups and CS02 placebo to match group will be compared with the analysis of covariance model including baseline HbA1c as covariate, and treatment groups and regions as fixed effects.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>T2DM With Inadequate Glycemic Control</condition>
  <arm_group>
    <arm_group_label>high dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS02 tablet and placebo tablet</intervention_name>
    <description>Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.</description>
    <arm_group_label>high dose of CS02</arm_group_label>
    <arm_group_label>low dose of CS02</arm_group_label>
    <arm_group_label>middle dose of CS02</arm_group_label>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with diagnosis of type 2 diabetes mellitus at least 12 weeks prior to Visit&#xD;
             1;&#xD;
&#xD;
          2. Outpatient, either male or female, aged 20 years or older from Taiwan and aged 18&#xD;
             years or older from united States; all subjects are ≤75 years old;&#xD;
&#xD;
          3. Subjects with a stable diet and exercise program for ≧8 weeks prior to Visit 1;&#xD;
&#xD;
          4. Subjects with HbA1c value ≧7.0% and ≦10.0% at Visit 1;&#xD;
&#xD;
          5. Subjects with a stable dose of metformin monotherapy of ≥1500 mg/day at least 12 weeks&#xD;
             before randomization (Visit 2);&#xD;
&#xD;
          6. Body mass index (BMI) between 20.0 and 45.0 kg/m2at Visit 1;&#xD;
&#xD;
          7. Subjects have adequate liver function, defined as serum total bilirubin≤1.5 times the&#xD;
             upper limit of normal (uLN); aspartate aminotransferase (AST) and alanine&#xD;
             aminotransferase (ALT)≤3 times uLN at Visit 1;&#xD;
&#xD;
          8. Subjects have estimated glomerular filtration rate (e-GFR)* values of≧ 45ml/min/1.73m2&#xD;
             at Visit1;&#xD;
&#xD;
          9. Female subjects of childbearing potential， defined as women≤ 55 years old or history&#xD;
             of amenorrhea ≤ 12 months prior to the study entry or not surgically sterile, must&#xD;
             have a negative pregnancy test at Visit 1 and agree to use a highly effective&#xD;
             contraceptive method during the study period;&#xD;
&#xD;
         10. Willing to provide a written informed consent form;&#xD;
&#xD;
         11. Willingness and ability to comply with treatment plans, scheduled visits, required&#xD;
             laboratory tests, and other study procedures;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with type 1 diabetes mellitus, secondary diabetes mellitus, or gestational&#xD;
             diabetes;&#xD;
&#xD;
          2. Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis,&#xD;
             with or without coma at Visit 1 or Visit 2;&#xD;
&#xD;
          3. Subjects with hypotension (average systolic pressure &lt; 90 mm Hg*) at Visit 1 or Visit&#xD;
             2;&#xD;
&#xD;
          4. Subjects with cardiogenic shock within 8 weeks prior to Visit 1;&#xD;
&#xD;
          5. Subjects with sick sinus syndrome, second- or third-degree atrioventricular block (AV&#xD;
             block);&#xD;
&#xD;
          6. Subjects with atrial flutter or atrial fibrillation and an accessory bypass tract&#xD;
             (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes);&#xD;
&#xD;
          7. Subjects with recurrence or history of transient ischemic attack or coronary artery&#xD;
             bypass surgery;&#xD;
&#xD;
          8. Subjects with history of cerebrovascular attack, myocardial infarction, serious&#xD;
             cardiac disease (New York Heart Association NYHA Class III to IV), left ventricular&#xD;
             ejection fraction≦40% within 12 weeks prior to Visit 1, or those with cardiovascular&#xD;
             disease or cerebrovascular disease that may affect the administration of IP tablets&#xD;
             (CS02) or its safety assessment in the opinion of the investigator or&#xD;
             sub-investigator;&#xD;
&#xD;
          9. Female subjects who are nursing or pregnant during the study period;&#xD;
&#xD;
         10. Subjects are on a weight loss program and not in the maintenance phase or have started&#xD;
             a weight loss medication including but not limited to Orlistat, Phentermine, Osymia,&#xD;
             or Belviq or have undergone bariatric surgery within 8 weeks prior to Visit 1 or any&#xD;
             type of surgery planned during the study;&#xD;
&#xD;
         11. Subjects with a clinically severe gastrointestinal disorder including diabetic&#xD;
             gastroparesis; irritable bowel disease; recurrent episodes of nausea, vomiting,&#xD;
             diarrhea and abdominal pain within 12 weeks prior to Visit 1;&#xD;
&#xD;
         12. Subjects have a history or current of substance or alcohol abuse;&#xD;
&#xD;
         13. Subjects have uncontrolled psychiatric disorder(s);&#xD;
&#xD;
         14. Subjects are less than 5 years free of malignancy (except for cured basal cell&#xD;
             carcinoma of skin and cured carcinoma in situ of the uterine cervix);&#xD;
&#xD;
         15. Subjects have participated in another clinical trial within the last 12 weeks prior to&#xD;
             Visit 1;&#xD;
&#xD;
         16. Subjects who are considered unreliable as to medication compliance or adherence to&#xD;
             scheduled appointments, or inappropriate for inclusion per investigators, judgments;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans general Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital_Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

